Carlos Bazan MD (He/Him)

Pulmonology•Oviedo, FL

Asthma & COPD, Pulmonary Rehabilitation, Clinical Pharmacology

A. Director Medical Affairs - Pulmonology Medical Science Liaison [Viatris - Mylan + Pfizer’s Upjohn]

Join to View Full Profile

1000 Alafaya Trail(East Orlando)Oviedo, FL 32765
Phone+1 516-589-2189

Summary

Carlos Bazan, MD is a Global Medical Affairs professional in Florida, (Viatris).
A Director Medical Affairs / Medical Science Liaison | Pulmonology | COPD

Education & Training

Universidad Autonoma de GuadalajaraClass of 1997

Clinical Trials

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Start of enrollment: 2001 Feb 01
Completed
Phase 3
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Start of enrollment: 2005 Mar 01
Completed
Phase 4
Basal Cell Carcinoma Recurrence After Mohs Surgery Start of enrollment: 2008 May 01
Completed
Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery Start of enrollment: 2007 Apr 01
Completed
A Phase IIa Study of KHK4563 Start of enrollment: 2011 Aug 01
Completed
Phase 2
Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Start of enrollment: 2013 Aug 01
Completed
Phase 3
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA Start of enrollment: 2014 Nov 19
Completed
Phase 3
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Start of enrollment: 2015 Jul 01
Completed
Phase 4
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes Start of enrollment: 2015 Dec 16
Terminated
Phase 3
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist Start of enrollment: 2016 Jun 30
Completed
Phase 3
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. Start of enrollment: 2017 Jul 07
Completed
Phase 3
Join now to see all

Research History

Country Manager (Spain)Ticagrelor (Bayer) -Galileo Study -Mount Sinai (New York City-Icahn)
Sr. Clinical Research AssociateBenralizumab (GSK) -Sirocco Study -Calima Study -Bora Study